# Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances

**Authors:** Khaled Mahmoud, Shady Swidan, Mohamed El-Nabarawi, Mahmoud Teaima

PMC · DOI: 10.1186/s12951-022-01309-9 · 2022-03-05

## TL;DR

This review explores how lipid-based nanoparticles offer a promising new approach for treating hepatocellular carcinoma, a common and deadly form of liver cancer.

## Contribution

The paper provides a comprehensive overview of lipid-based nanoparticle types and targeting strategies for hepatocellular carcinoma treatment.

## Key findings

- Lipid-based nanoparticles show potential in improving drug delivery and treatment outcomes for hepatocellular carcinoma.
- Various nanoparticle types and targeting methods, such as passive and active targeting, are reviewed for enhanced tumor uptake.
- Nanoparticles offer advantages over conventional drug treatments by improving specificity and reducing side effects.

## Abstract

Liver cancer is considered one of the deadliest diseases with one of the highest disease burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is considered to be the most common type. Multiple conventional approaches are being used in treating hepatocellular carcinoma. Focusing on drug treatment, regular agents in conventional forms fail to achieve the intended clinical outcomes. In order to improve the treatment outcomes, utilizing nanoparticles—specifically lipid based nanoparticles—are considered to be one of the most promising approaches being set in motion. Multiple forms of lipid based nanoparticles exist including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, phytosomes, lipid coated nanoparticles, and nanoassemblies. Multiple approaches are used to enhance the tumor uptake as well tumor specificity such as intratumoral injection, passive targeting, active targeting, and stimuli responsive nanoparticles. In this review, the effect of utilizing lipidic nanoparticles is being discussed as well as the different tumor uptake enhancement techniques used.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256), liver cancer (MONDO:0002691)

## Full-text entities

- **Genes:** BID (BH3 interacting domain death agonist) [NCBI Gene 637] {aka FP497}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, IZUMO1R (IZUMO1 receptor, JUNO) [NCBI Gene 390243] {aka FOLR4, FR-delta, Folbp3, JUNO}, Ldlr (low density lipoprotein receptor) [NCBI Gene 16835] {aka Hlb301}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, Blvrb (biliverdin reductase B) [NCBI Gene 233016], MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, Anpep (alanyl aminopeptidase, membrane) [NCBI Gene 16790] {aka AP-M, AP-N, Apn, Cd13, P150}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Thy1 (thymus cell antigen 1, theta) [NCBI Gene 21838] {aka CD90, T25, Thy-1, Thy-1.2, Thy1.1, Thy1.2}, IGF2R (insulin like growth factor 2 receptor) [NCBI Gene 3482] {aka CD222, CI-M6PR, CIMPR, M6P-R, M6P/IGF2R, MPR 300}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, MS4A1 (membrane spanning 4-domains A1) [NCBI Gene 931] {aka B1, Bp35, CD20, CVID5, FMC7, LEU-16}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, Bax (BCL2-associated X protein) [NCBI Gene 12028], PAEP (progestagen associated endometrial protein) [NCBI Gene 5047] {aka GD, GdA, GdF, GdS, PAEG, PEP}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Ldlr (low density lipoprotein receptor) [NCBI Gene 300438] {aka LDLRA}, Stat5a (signal transducer and activator of transcription 5A) [NCBI Gene 24918] {aka Stat5}, Cdkn1b (cyclin dependent kinase inhibitor 1B) [NCBI Gene 12576] {aka Kip1, p27, p27Kip1}, Met (met proto-oncogene, receptor tyrosine kinase) [NCBI Gene 17295] {aka HGF, HGFR, Par4, c-Met}, MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217] {aka ASK1, MAPKKK5, MEKK5}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, Tat (tyrosine aminotransferase) [NCBI Gene 234724], PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, ERBB4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 2066] {aka ALS19, HER4, p180erbB4}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, MPO (myeloperoxidase) [NCBI Gene 4353], Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Casp8 (caspase 8) [NCBI Gene 12370] {aka CASP-8, FLICE, MACH, Mch5}, THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070] {aka CD90, CDw90}, PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, ERBB3 (erb-b2 receptor tyrosine kinase 3) [NCBI Gene 2065] {aka ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1}, Abcg2 (ATP binding cassette subfamily G member 2 (Junior blood group)) [NCBI Gene 26357] {aka ABC15, ABCP, BCRP, Bcrp1, MXR, MXR1}, RABEP2 (rabaptin, RAB GTPase binding effector protein 2) [NCBI Gene 79874] {aka FRA}, Pla2g1b (phospholipase A2, group IB, pancreas) [NCBI Gene 18778] {aka Pla2a, sPLA2IB}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, ASGR1 (asialoglycoprotein receptor 1) [NCBI Gene 432] {aka ASGPR, ASGPR1, CLEC4H1, HL-1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}
- **Diseases:** lung cancer (MESH:D008175), kidney toxicity (MESH:D007674), Cirrhosis (MESH:D005355), ischemic necrosis (MESH:D005271), hemolysis (MESH:D006461), necrotic (MESH:D009336), Cancer (MESH:D009369), hepatic nodules (MESH:D016606), Liver Diseases (MESH:D008107), hypoxic (MESH:D002534), Cancer of the Liver (MESH:D006528), Cytotoxicity (MESH:D064420), BCRP (MESH:D001943), deaths (MESH:D003643), alcoholic liver disease (MESH:D008108), diabetes (MESH:D003920), hepatocellular necrosis (MESH:D047508), cirrhotic liver (MESH:D008103), cervical carcinoma (MESH:D002583), liver tumor (MESH:D008113), hemochromatosis (MESH:D006432), nonalcoholic steatohepatitis (MESH:D065626), hepatic (MESH:D056486), hepatitis B and C viruses (MESH:D006509), DSPC (MESH:D053307), colon cancer (MESH:D015179), MDR (MESH:D018088), CD (MESH:D003424), apoptosis (MESH:D065703), obesity (MESH:D009765), Hyperthermia (MESH:D005334), MPS (MESH:D010585), gastric cancer (MESH:D013274), Chronic inflammation (MESH:D007249), hypoxia (MESH:D000860), hepatic metastasis (MESH:D009362), infection (MESH:D007239), preneoplastic lesions (MESH:D011230), Ehrlich ascites carcinoma (MESH:D002286), fatty liver diseases (MESH:D005234)
- **Chemicals:** ATP (MESH:D000255), Triiodothyronine (MESH:D014284), Fucoidan (MESH:C007789), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (MESH:C038089), diosmin (MESH:D004145), vinorelbine (MESH:D000077235), dicetyl phosphate (MESH:C002290), iron oxide (MESH:C000499), Peceol (MESH:C482692), 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (MESH:C081581), Sodium chloride (MESH:D012965), perfluoropropane (MESH:C042852), norcantharidin (MESH:C069741), Galactomannan (MESH:C012990), acetic acid (MESH:D019342), lecithin (MESH:D054709), lactobionic acid (MESH:C005608), calcium carbonate (MESH:D002119), Labrafil  M1944 CS (MESH:C514708), silymarin (MESH:D012838), propylene glycol (MESH:D019946), water (MESH:D014867), PEG4000 (MESH:C000595214), CD (MESH:D002104), lipid bilayer (MESH:D008051), carboxymethyl chitosan (MESH:C514968), cholesterol ester (MESH:D002788), arabinogalactan (MESH:C005653), DEN (MESH:D004052), ganoderic acid (MESH:C556862), 11-DGA-3-O-Gal (-), perfluoropentane (MESH:C008806), diacetyl phosphate (MESH:C005146), NADP + (MESH:D009249), RGD (MESH:C047981), GA (MESH:D006034), Cremophor  RH 40 (MESH:C022131), Curcumin (MESH:D003474), Ceramide (MESH:D002518), Ce6 (MESH:C062985), DC (MESH:D003841), carbohydrate (MESH:D002241), dipalmitoylphosphatidyl ethanolamine (MESH:C007510), glyceryl monostearate (MESH:C048159), Oleanolic acid (MESH:D009828), arsenic trioxide (MESH:D000077237), cabozantinib (MESH:C558660), stigmastanol (MESH:C021255), oleic acid (MESH:D019301), donafenib (MESH:C000710249), Fasudil (MESH:C049347), Lactose (MESH:D007785), 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (MESH:D004134), viramidine (MESH:C026956), Tyrphostin AG-1478 (MESH:C101044), ethyl oleate (MESH:C033180), 5-FU (MESH:D005472), aflatoxin (MESH:D000348), Disulfide (MESH:D004220), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (MESH:C020888)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Glycyrrhiza (licorice, genus) [taxon 46347], Glycine max (soybean, species) [taxon 3847], Nigella sativa (black-caraway, species) [taxon 555479]
- **Cell lines:** Chang — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0238), Huh7.5 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_7927), HepG2H22L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), HCA-1JHH-7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_2805), H9C2 — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_0286), CFSC-2G — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_4U34), HCA-1 — Homo sapiens (Human), Cervical adenocarcinoma, Cancer cell line (CVCL_2916), ME — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_L912), BEL-7402 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_5492), MHHC97H — Homo sapiens (Human), Ataxia telangiectasia syndrome, Finite cell line (CVCL_WX49), SGC-7901 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0520), HepG2 HepG2 tumor — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), NIH 3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), L02SMMC-7721 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0534), H4IIE — Rattus norvegicus (Rat), Rat hepatocellular carcinoma, Cancer cell line (CVCL_0284), 293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), LX-2 — Homo sapiens (Human), Transformed cell line (CVCL_5792), HepG2HCC97HH9c2H22 — Bos taurus (Bovine), Spontaneously immortalized cell line (CVCL_HG40), H22 — Homo sapiens (Human), Peripheral primitive neuroectodermal tumor of bone, Cancer cell line (CVCL_1E32), SMMC-772 — Mus musculus (Mouse), Embryonic stem cell (CVCL_PV70), B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), HepG2L02Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), 7404 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_6568), HLF — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_2947), Huh7L02 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_U459), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), SK-HEP-1 — Homo sapiens (Human), Liver and intrahepatic bile duct epithelial neoplasm, Cancer cell line (CVCL_0525), CL1-5 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_D521), WRL-68 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0581), HCC36 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_VI90), B16 — Mus musculus (Mouse), Hybridoma (CVCL_U043), HA22T — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_7046), kidney — Homo sapiens (Human), Undefined cell line type (CVCL_WH75), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), L02 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_6926), PLC/PRF/5 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0485), HEPS tumor — Mesocricetus auratus (Golden hamster), Hamster neoplasm, Cancer cell line (CVCL_Y446), NRM — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_C7RQ), VX2 — Oryctolagus cuniculus (Rabbit), Rabbit neoplasm, Cancer cell line (CVCL_3864), Mahlavu — Homo sapiens (Human), Hepatocellular carcinoma, Cancer cell line (CVCL_0405), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), Hep3B — Homo sapiens (Human), Childhood hepatocellular carcinoma, Cancer cell line (CVCL_0326), NCI-H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060), A549DDP — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_C0W4), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), Madine-Darby Canine — Canis lupus familiaris (Dog), Spontaneously immortalized cell line (CVCL_0422), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), LO2 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_C7SD), HepG2Huh7HC — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8898455/full.md

---
Source: https://tomesphere.com/paper/PMC8898455